John Evans, MBA
John Evans joined Beam Therapeutics in 2017 as chief executive officer, bringing significant experience as a company-builder, dealmaker, and drug developer in the biotech industry. Mr. Evans is also a venture partner with ARCH Venture Partners. Mr. Evans was previously an early employee and member of the leadership team at Agios Pharmaceuticals (AGIO), most recently serving as senior vice president for corporate development and portfolio leadership. At Agios, Mr. Evans served as IDH portfolio executive, providing strategic and operational leadership for a portfolio of first-in-class IDH inhibitors, including IDHIFA and TIBSOVO. He helped initiate and lead Agios’s landmark alliance with Celgene, resulting in over $600 million of funding and investments across multiple innovative research collaborations in cancer metabolism. He also initiated and co-led Agios’s strategic expansion into rare genetic diseases of metabolism. Prior to joining Agios, Mr. Evans worked at Infinity Pharmaceuticals and in the pharmaceuticals practice of McKinsey & Company. Mr. Evans holds an MBA in healthcare management from Wharton, a master’s degree in biotechnology from the University of Pennsylvania, and a B.A. in English with distinction from Yale University.